Biointelect Venturer

Biointelect Venturer is designed to accelerate Australian scientific innovation for the prevention of infectious diseases. The fund helps innovators to advance early-stage breakthroughs in vaccines, immunotherapies and related technologies from concept to commercial and investment readiness.

The program prioritises:

• Innovations addressing high unmet clinical needs;
• Solutions with global health and regional security benefits; and
• Technologies with strong commercialisation potential.

Eligible technology types include:

• Prophylactic vaccines;
• Prophylactic immunotherapies;
• Related technologies (e.g. delivery systems, adjuvants or platforms) that enable or enhance prevention;
• Other modalities that reduce infection risk or transmission, such as diagnostics, biomarkers and prophylactic drugs.

Note: Therapeutic interventions for existing infections, AI / digital health tools and devices for treatments are not eligible.

This program offers grant funding from a total pool of $25 million, distributed across three stages:

• Up to $1.5 million for projects at TRL 3-4;
• Up to $3 million for projects at TRL 5-6.

Top-up funding is available to successful applicants up to a total grant value of $5 million.

Eligible applicants must:

• Be an Australian small-to-medium enterprise (SME) (registered entity with less than 200 employees); or
• Be a researcher at an Australian university or medical research institute willing to establish an SME before funding.

Projects must:

• Focus on preventing a specific infectious disease in humans, not on treating or managing other conditions; and
• Be within TRL 3-6 at application time.
   

Note: Projects at TRL 2 may be considered by exception if they are about to progress to TRL 3 or have a credible plan to reach TRL 4 within two years.

Expressions of Interest (EOI) applications close 19 December 2025.